Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy Plus Bacillus Calmette-Guérin for High-Risk Nonmuscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN: Erratum

Daniel D. Joyce, Vidit Sharma, Grace E. Ratcliff, Daniel A. Barocas, Sam S. Chang, David F. Penson, Vignesh T. Packiam, Girish Kulkarni, Kevin M. Wymer, Stephen A. Boorjian

Open source

DOI: 10.1097/ju.0000000000005262
Published: 2026-12
Container: Journal of Urology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/ju.0000000000005262,
  title = {Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy Plus Bacillus Calmette-Guérin for High-Risk Nonmuscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN: Erratum},
  author = {Daniel D. Joyce and Vidit Sharma and Grace E. Ratcliff and Daniel A. Barocas and Sam S. Chang and David F. Penson and Vignesh T. Packiam and Girish Kulkarni and Kevin M. Wymer and Stephen A. Boorjian},
  year = {2026},
  journal = {Journal of Urology},
  doi = {10.1097/ju.0000000000005262},
  url = {https://doi.org/10.1097/ju.0000000000005262}
}

RIS

TY  - JOUR
TI  - Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy Plus Bacillus Calmette-Guérin for High-Risk Nonmuscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN: Erratum
AU  - Daniel D. Joyce
AU  - Vidit Sharma
AU  - Grace E. Ratcliff
AU  - Daniel A. Barocas
AU  - Sam S. Chang
AU  - David F. Penson
AU  - Vignesh T. Packiam
AU  - Girish Kulkarni
AU  - Kevin M. Wymer
AU  - Stephen A. Boorjian
PY  - 2026
JO  - Journal of Urology
DO  - 10.1097/ju.0000000000005262
UR  - https://doi.org/10.1097/ju.0000000000005262
ER  -

APA

Joyce, D. D., Sharma, V., Ratcliff, G. E., Barocas, D. A., Chang, S. S., Penson, D. F., Packiam, V. T., Kulkarni, G., Wymer, K. M., & Boorjian, S. A. (2026). Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy Plus Bacillus Calmette-Guérin for High-Risk Nonmuscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN: Erratum. Journal of Urology. https://doi.org/10.1097/ju.0000000000005262

Source records

crossref · retrieved 2026-11-10T19:06:34.520Z